Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2+ Gastric Cancer (DESTINY-Gastric03)

Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2+ Gastric Cancer (DESTINY-Gastric03)
Condition:   Gastric Cancer
Interventions:   Drug: Fluorouracil (5-FU);   Drug: Capecitabine;   Biological: Durvalumab;   Drug: Oxaliplatin;   Biological: Trastuzumab;   Drug: Trastuzumab deruxtecan;   Drug: Cisplatin
Sponsors:   AstraZeneca;   Daiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, Tokyo
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

June 26, 2020 / by / in
Comments